Skip to main content
Parmax Pharma Limited logo

Parmax Pharma Limited — Investor Relations & Filings

Ticker · 540359 ISIN · INE240T01014 LEI · 335800838LWBPQU5MJ05 BSE.NS Manufacturing
Open in API
Filings indexed 11 across all filing types
Latest filing 2026-06-09 Proxy Solicitation & In…
Country IN India
Listing BSE.NS 540359

About Parmax Pharma Limited

https://www.parmaxpharma.com/

Parmax Pharma Limited specializes in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical formulations. The company’s product range encompasses various delivery systems, including solid orals like tablets and capsules, as well as liquid preparations and topical ointments. Its therapeutic focus spans several categories, such as anti-infectives, analgesics, gastrointestinal agents, and respiratory medications. The organization maintains a commitment to stringent quality control measures and adheres to Good Manufacturing Practices (GMP) to ensure product safety and therapeutic effectiveness. By leveraging advanced production facilities and a comprehensive distribution infrastructure, the company provides healthcare solutions across multiple markets. Its core operations prioritize formulation research and the scaling of manufacturing processes to meet diverse clinical requirements.

Recent filings

Filing Released Lang Actions
Notice of EGM scheduled to be held on July 02, 2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal Notice of the Extraordinary General Meeting (EGM) including the agenda, resolutions to be proposed, voting details, and instructions for shareholders. It is not reporting results, nor is it the actual EGM minutes or transcript. Rather, it is the solicitation of shareholder votes for the EGM. This fits the definition of Proxy Solicitation & Information Statement (PSI).
2026-06-09 English
Share purchase agreement and Public Announcement
M&A Activity Classification · 93% confidence The document is a mandatory disclosure under Regulation 30 of SEBI LODR to BSE regarding acquirers and persons acting in concert seeking to acquire control of the company through a combination of preferential allotment, secondary acquisition via a share purchase agreement, and an open offer. It details the SPA terms, preferential share/warrant issuances tied to the control acquisition, and post-transaction board reconstitution. This is clearly an announcement of a takeover bid/acquisition transaction rather than a routine earnings release, proxy, or standalone financial report. Accordingly, it falls under M&A Activity (Code: TAR).
2026-06-09 English
Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulation 3(1) And Regulation 4 Read with Regulation 13, Regulation 14 And Regulation ....
M&A Activity Classification · 85% confidence The document is a public announcement under SEBI (SAST) Regulations, detailing an open offer by acquirers and persons acting in concert for substantial acquisition of shares and takeover of the target company. It describes the transaction structure, offer size, preferential issue, share purchase agreement, regulatory compliances, and detailed takeover terms. This clearly falls under announcements related to merger or takeover bids, which matches the M&A Activity category (Code: TAR).
2026-06-09 English
Issue of Shares and Warrants on Preferential basis pursuant to SEBI ICDR Regulations
Share Issue/Capital Change Classification · 86% confidence The document is a stock exchange disclosure under SEBI LODR Regulations providing the outcome of a board meeting which includes proposals to increase authorised share capital, adoption of new Articles, and a detailed preferential issue of equity shares and warrants to raise funds. This is an announcement of new share issuance and capital structure changes. It does not contain full financial statements or board appointments, but specifically describes a share issue transaction. Accordingly, it falls under Share Issue/Capital Change (SHA).
2026-06-08 English
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2026 ,inter alia, to consider and approve Fund raising
Regulatory Filings Classification · 85% confidence The document is an intimation to the stock exchange regarding an upcoming Board meeting and closure of the trading window under SEBI Listing Regulations. It does not contain financial results (so not ER/IR), nor is it a full report (10-K, IR), nor an actual change in board composition (MANG). It is a regulatory compliance announcement, fitting into the generic Regulatory Filings (RNS) category.
2026-06-03 English
Results for Financial Results for Quarter and Financial Year ended March 31, 2026
Interim / Quarterly Report Classification · 85% confidence The document is a submission to the Bombay Stock Exchange under SEBI (LODR) Regulations of the Board’s approval of and attached standalone financial results for the quarter ended and financial year ended March 31, 2026, together with the independent auditor’s report. It contains substantive financial data (the audited results and auditor’s report), not merely an announcement or link, and is not the full statutory Annual Report (10-K) but rather the period‐end financial results for a quarter and year. Therefore, it best fits the definition of an Interim / Quarterly Report (IR). FY 2026
2026-06-03 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.